Status
Conditions
Treatments
About
The objective of our study is to evaluate the functional and morphological imaging variations at 24 and 52 weeks compared to baseline during TCZ-treatment and 6 months after the suspension of TCZ. We will also evaluate the variations of aortic dilatation during the study period using the PET/CT in comparison with an hystorical cohort of patients with LVV treated with GCs only and longitudinally followed at our rheumatology division.
Full description
Trial Design Monocentric observational study, single arm, based on imaging of patients with active Large Vessel Giant Cell Arteritis (LV-GCA) , treated with Tocilizumab (TCZ) s.c. and with ultra-short glucocorticosteroids (GCs).
Duration of study per Subject 52 weeks of observation during standard of care (SOC) and 24 weeks of follow-up
Target Population Patients aged older than 50 years with active large vessel giant cell arteritis (LV-GCA) based on evidence of large vasculitis at imaging.
Patients with active disease will be enrolled according to the following inclusion criteria:
Primary Objectives
Secondary Objectives
Enrollment
Sex
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Exclusion Criteria
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal